AVPR2 and autosomal dominant polycystic kidney disease: The data here support the activity of tolvaptan at the vasopressin V2 receptor in children and adolescents with ADPKD, indicate the feasibility of a modified dosing strategy, and provide initial evidence of effects on TKV growth and eGFR decline that require further research.